Abstract | BACKGROUND: METHODS:
Quinupristin/dalfopristin was administered according to the manufacturer's recommendations. Clinical and laboratory data were recorded for each patient. RESULTS: The infections treated comprised six cases of bacteremia and two of peritonitis. All patients had serious underlying conditions. Seven patients recovered fully. One patient died, having experienced a relapse of his infection after quinupristin/dalfopristin was discontinued. None of the patients experienced side effects or other adverse events. CONCLUSION:
Quinupristin/dalfopristin was well-tolerated and generally effective in children with infections caused by VREF. There is increasing evidence that it may be more effective than other currently available antibiotics in some such patients.
|
Authors | J W Gray, P J Darbyshire, S V Beath, D Kelly, J R Mann |
Journal | The Pediatric infectious disease journal
(Pediatr Infect Dis J)
Vol. 19
Issue 3
Pg. 234-8
(Mar 2000)
ISSN: 0891-3668 [Print] United States |
PMID | 10749466
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Virginiamycin
- quinupristin
- dalfopristin
|
Topics |
- Adolescent
- Anti-Bacterial Agents
(adverse effects, therapeutic use)
- Child
- Child, Preschool
- Drug Therapy, Combination
(adverse effects, therapeutic use)
- Enterococcus faecium
(isolation & purification)
- Female
- Gram-Positive Bacterial Infections
(drug therapy, microbiology, mortality)
- Humans
- Infant
- Male
- Treatment Outcome
- Vancomycin Resistance
- Virginiamycin
(adverse effects, analogs & derivatives, therapeutic use)
|